Serum level of vascular endothelial growth factor is decreased by hormone replacement therapy in postmenopausal women without hypercholesterolemia

Atherosclerosis

Volumn 148, Issue 1, 2000, Pages 189-195

  Sumino, Hiroyuki ^a   Nakamura, Tetsuya ^b   Ichikawa, Shuichi ^a   Kanda, Tsugiyasu ^b   Sakamaki, Tetsuo ^b   Sato, Kunio ^b   Kobayashi, Isao ^b   Nagai, Ryozo ^b  

^a Cardiovasc Hosp of Central Japan   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Estrogen; High density lipoprotein; Hormone replacement therapy; Low density lipoprotein; Postmenopausal women; Vascular endothelial growth factor

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CONJUGATED ESTROGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; MEDROXYPROGESTERONE ACETATE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ENDOTHELIAL GROWTH FACTORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LYMPHOKINES; MIDDLE AGED; REFERENCE VALUES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033991696     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00262-2     Document Type: Article

References (25)

1. Wenger N.K., Speroff L., Packard B. Cardiovascular health and disease in women. N. Engl. J. Med. 329:1993;247-256.
2. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63.
3. Walsh B.W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F.M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Eng. J. Med. 325:1991;1196-1204.
4. Notelovitz M. Estrogen replacement therapy: indications, contraindications, and agent selection. Am. J. Obstet. Gynecol. 161:1989;1832-1841.
5. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K. et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N. Engl. J. Med. 328:1993;1069-1075.
6. Best P.J.M., Berger P.B., Miller V.M., Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann. Intern. Med. 128:1998;285-288.
7. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:1989;851-858.
8. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312.
9. Connolly D.T., Heuvelman D.M., Nelson R., Olander J.V., Eppley B.L., Delfino J.J. et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84:1989;1470-1478.
10. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
11. Takeshita S., Rossow S.T., Kearney M., Zheng L.P., Bauters C., Bunting S. et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am. J. Pathol. 147:1995;1649-1660.
12. Couffinhal T., Kearney M., Witzenbichler B., Chen D., Murohara T., Losordo D.W. et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am. J. Pathol. 150:1997;1673-1685.
13. Inoue M., Itoh H., Ueda M., Naruko T., Kojima A., Chun T.H. et al. Expression of vascular endothelial growth factor (VEGF) in human coronary atherosclerosis and its gene regulation by oxidized LDL (Ox-LDL): VEGF as a possible progression factor for human atherosclerosis. Circulation. 96((Suppl. I)):1997;I2.
14. Dulak J., Polus M., Guevara I., Polus A., Hartwich J., Dembinska-Kiec A. Regulation of inducible nitric oxide synthase (iNOS) and GTP cyclohydrolase I (GTP-CH I) gene expression by ox-LDL in rat vascular smooth muscle cells. J. Physiol. Pharmacol. 48:1997;689-697.
15. Adams M.R., Kaplan J.R., Manuck S.B., Koritnik D.R., Parks J.S., Wolfe M.S. et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis. 10:1990;1051-1057.
16. Stevenson J.C., Crook D., Godsland I.F. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis. 98:1993;83-90.
17. Holme I., Solberg L.A., Weissfeld L., Helgeland A., Hjermann I., Leren P. et al. Coronary risk factors and their pathway of action through coronary raised lesions, coronary stenosis and coronary death: multivariate statistical analysis of an autopsy series: the Oslo Study. Am. J. Cardiol. 55:1985;40-47.
18. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
19. Romm P.A., Green C.E., Reagan K., Rackley C.E. Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease. Am. J. Cardiol. 67:1991;479-483.
20. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med. 323:1990;1289-1298.
21. Watts G.F., Lewis B., Brunt J.N.H., Lewis E.S., Coltart D.J., Smith L.D.R. et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
22. Romos M.A., Kuzuya M., Esaki T., Miura S., Satake S., Asai T. et al. Induction of macrophage VEGF in response to oxidized LDL and VEGF accumulation in human atherosclerotic lesions. Arterioscle. Thromb. Vasc. Biol. 18:1998;1188-1196.
23. Cullinan-Bove K., Koos R.D. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth. Endocrinology. 133:1993;829-837.
24. Shweiki D., Itin A., Neufeld G., Gitay-Goren H., Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Invest. 91:1993;2235-2243.
25. Hyder S.M., Stancel G.M., Chiappetta C., Murthy L., Boettger-Tong H.L., Makela S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res. 56:1996;3954-3960.